Precision Optics Corp.
POCI Healthcare Medical Instruments & Supplies
Precision Optics Corp.’s revenue for fiscal 2026 (year ended June 2026) was $31.5 million, up 65.2% from fiscal 2025. In the quarter to June 2026, revenue grew 42.0%, EPS grew 117.4%, free cash flow fell 45.6% and total debt fell 31.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow POCI
Precision Optics Corp. (POCI) EV/Sales
As of 16 October 2026, Precision Optics Corp. (POCI) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from 0.5× (January 2015) to 9.6× (December 2021); the current reading is higher than 8% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 1.1× | (36.56%) |
| FY2025 | 1.7× | (17.77%) |
| FY2024 | 2.1× | 28.98% |
| FY2023 | 1.6× | (21.85%) |
| FY2022 | 2.1× | 4.20% |
| FY2021 | 2.0× | 13.14% |
| FY2020 | 1.8× | 12.58% |
| FY2019 | 1.6× | 33.12% |
| FY2018 | 1.2× | (23.34%) |
| FY2017 | 1.6× | 61.50% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.1× | 28.49% |
| Mar 2026 | 0.9× | (36.21%) |
| Dec 2025 | 1.4× | (13.90%) |
| Sep 2025 | 1.6× | (10.12%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −14.4× |
| MBOT Microbot Medical Inc. compare | −2.9× |
| NYXH Nyxoah SA compare | 0.7× |
| POCI Precision Optics Corp. | 0.9× |
| HBIO Harvard Bioscience, Inc. compare | 1.1× |
| NEPH Nephros Inc. compare | 1.7× |
| MLSS Milestone Scientific, Inc. compare | 3.1× |
| STXS Stereotaxis Inc. compare | 3.1× |
| ZTEKF Zentek Ltd. compare | 288× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)